


# Minicircle and Miniplasmid DNA Vectors

The Future of Non-Viral  
and Viral Gene Transfer

Edited by Martin Schleef





## The Editor

**Dr. Martin Schleef**  
PlasmidFactory GmbH & Co. KG  
Meisenstraße 96  
33607 Bielefeld  
Germany

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

**Library of Congress Card No.:** applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at (<http://dnb.d-nb.de>).

© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Print ISBN:** 978-3-527-32456-9

**ePDF ISBN:** 978-3-527-67043-7

**ePub ISBN:** 978-3-527-67044-4

**mobi ISBN:** 978-3-527-67045-1

**oBook ISBN:** 978-3-527-67042-0

**Typesetting** Thomson Digital, Nojda, India

**Printing and Binding** Markono Print Media Pte Ltd, Singapore

**Cover Design** Adam-Design, Weinheim

Printed on acid-free paper

## Contents

**List of Contributors** XIII

**Preface** XXI

- 1 Minicircle Patents: A Short IP Overview of Optimizing Nonviral DNA Vectors** 1  
*Martin Grund and Martin Schleef*  
References 6
  
- 2 Operator–Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes** 7  
*Rocky M. Cranenburgh*
  - 2.1 Introduction 7
  - 2.2 Antibiotics and Metabolic Burden 7
  - 2.3 The Mechanism of ORT 8
  - 2.4 ORT Strain Development 9
  - 2.5 ORT Miniplasmids 12
  - 2.6 DNA Vaccine and Gene Therapy Vectors 13
  - 2.7 ORT-VAC: Plasmid-Based Vaccine Delivery Using *Salmonella enterica* 14
  - 2.8 Recombinant Protein Expression 18
  - 2.9 Conclusions and Future Developments 19  
References 19
  
- 3 Selection by RNA–RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids** 23  
*Juergen Mairhofer and Reingard Grabherr*
  - 3.1 Gene Therapy and DNA Vaccines: Emerging Technologies 23
  - 3.1.1 Therapeutic Plasmids: General Design Principles 24
  - 3.2 Therapeutic Plasmids: Novel Design and the Problem of Selection 25
  - 3.2.1 Replication Control of ColE1-Type Plasmids as an Alternative Selection Marker 26
  - 3.2.2 The MINIback Concept: Selection by RNA–RNA Interaction 28
  - 3.2.3 Improved Production Processes by MINIback Plasmids 30

3.2.4	Improving Sequence Composition	32
3.2.5	Efficient Gene Transfer	32
3.3	Conclusions	33
	Acknowledgments	33
	References	33
<b>4</b>	<b>Plasmid-Based Medicinal Products – Focus on pFAR: A Miniplasmid Free of Antibiotic Resistance Markers</b>	<b>37</b>
	<i>Corinne Marie, Mickaël Quiviger, Helen Foster, George Dickson, and Daniel Scherman</i>	
4.1	Introduction: Rationale for the Development of Biosafe DNA Plasmid Vectors	37
4.2	Specific Requirements for the Use of DNA Product as Medicines	39
4.2.1	Requirements for Plasmid Quality and Purity	39
4.2.2	Requirements for the Removal of Antibiotic Resistance Markers from Plasmid DNA	40
4.2.2.1	Requirements for Biosafe Plasmids	40
4.2.2.2	Positive Impact on the Removal of Antibiotic Resistance Markers	41
4.2.2.3	Effect of Plasmid Size on Gene Transfer Efficiency <i>In Vitro</i> and <i>In Vivo</i>	41
4.3	Nonviral Gene Vectors Devoid of Antibiotic Resistance Markers	43
4.3.1	Generalities	43
4.3.2	Selection Systems Devoid of Antibiotic Resistance Markers	43
4.3.2.1	Complementation of Host Auxotrophy by a Function-Encoded Plasmid	43
4.3.2.2	The Operator–Repressor Titration (ORT) System	44
4.3.2.3	Protein-Based Antidote/Poison Selection Systems	44
4.3.2.4	RNA-Based Selection Marker	44
4.3.2.5	Suppression of a Nonsense Mutation	45
4.4	The pFAR Plasmid Family	46
4.4.1	Description of the Antibiotic-Free Selection System	46
4.4.2	pFAR Vectors Promote Efficient Expression in Several Types of Mammalian Cells	49
4.4.2.1	<i>In Vitro</i> Transfection Study	49
4.4.2.2	<i>In Vivo</i> Transfection Studies	50
4.4.3	Concluding Remarks on the pFAR4 Biosafe Miniplasmid	51
4.5	Concluding Remarks and Perspectives	52
	Acknowledgments	53
	References	53
<b>5</b>	<b>Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency</b>	<b>59</b>
	<i>Christof Maucksch, Bronwen Connor, and Carsten Rudolph</i>	
5.1	Introduction	59
5.2	Plasmid DNA Topology and Size	60

5.3	Plasmid DNA Concatemers	62
5.4	Conclusions	67
	Acknowledgments	67
	References	68
<b>6</b>	<b>Analytical Tools in Minicircle Production</b>	<b>71</b>
	<i>Anja Rischmüller, Martina Viefhues, Mareike Dieding, Markus Blaesen, Marco Schmeer, Ruth Baier, Dario Anselmetti, and Martin Schleeß</i>	
6.1	Introduction	71
6.1.1	Gene Transfer for Therapy, Vaccination, and Stem Cells	71
6.1.2	Plasmids	72
6.1.3	Minicircle Systems	73
6.2	Production of Minicircles	74
6.2.1	The Parental Plasmid	74
6.2.2	Cultivation and Induction	74
6.2.3	Minicircle Preparation	77
6.3	Analytics of Minicircle Production	79
6.3.1	In-Process Control	79
6.3.1.1	Atomic Force Microscopy	79
6.3.1.2	Capillary Gel Electrophoresis	81
6.3.1.3	Continuous Flow Separation in Microfluidic Channels	82
6.3.2	Finished Product Control	86
6.4	Future Goals	88
	Acknowledgments	88
	References	89
<b>7</b>	<b>Utilizing Minicircle Vectors for the Episomal Modification of Cells</b>	<b>93</b>
	<i>Orestis Argyros, Suet-Ping Wong, Charles Coutelle, and Richard P. Harbottle</i>	
7.1	Introduction	93
7.2	Studies that Show Passive Episomal Maintenance of Minicircles	
	<i>In Vivo</i>	94
7.3	Principles of Generating Minicircle Vectors Able to Support Episomal Maintenance	97
7.3.1	Episomal Maintenance of Minicircle S/MAR Vectors Generated by FLP Recombinase	<i>In Vitro</i> 98
7.3.2	Episomal Maintenance of Minicircle S/MAR Vectors Generated Using Cre Recombinase	<i>In Vitro</i> 99
7.3.3	Episomal Maintenance of S/MAR Vectors in Bovine and Murine Zygotes	101
7.4	Episomal Maintenance of S/MAR Minicircles	<i>In Vivo</i> 102
7.5	Potential of Episomal Replication of S/MAR Minicircle Vectors	104
7.6	Possible Mechanisms Promoting the Episomal Maintenance of Minicircle Vectors	105
7.6.1	Histone Modifications	106
7.6.2	CpG Dinucleotide Content Reduction	106

7.6.3	Vector Establishment in the Correct Nuclear Compartment	107
7.6.4	Access to Replication Machinery by S/MARS	107
7.7	Conclusions	110
	References	110
<b>8</b>	<b>Replicating Minicircles: Overcoming the Limitations of Transient and Stable Expression Systems</b>	<b>115</b>
	<i>Kristina Nehlsen, Sandra Broll, Raju Kandimalla, Niels Heinz, Markus Heine, Stefanie Binius, Axel Schambach, and Jürgen Bode</i>	
8.1	Gene Therapy: The Advent of Novel Vector Vehicles	115
8.1.1	Nonviral Vectors Avoiding Genomic Disturbances	116
8.1.2	Independent Expression Units: Chromatin Domains	116
8.1.2.1	S/MARS: a Unifying Principle	118
8.1.2.2	S/MAR Actions Are Multifold and Context Dependent	119
8.1.2.3	Stress-Induced Duplex Destabilization: a Unifying Property of S/MARS	121
8.1.2.4	Chromosome-Based Expression Strategies: Episomes and/or Predetermined Integration Sites (RMCE)	123
8.2	Replicating Nonviral Episomes	123
8.2.1	Can the Yeast ARS Principle Be Verified for Mammalian Cells?	125
8.2.2	ARS and S/MARS: Common (SIDD-) Properties	125
8.2.3	S/MAR Plasmids: Verification of the Concept	126
8.2.3.1	Transcription into the S/MAR: Directionality and Rate	126
8.2.3.2	Cell and Nuclear Permeation	128
8.2.3.3	Nuclear Association Sites	129
8.2.3.4	RMCE-Based Elaboration Following Establishment	130
8.2.4	Remaining Shortcomings and Their Solution	132
8.2.4.1	Establishment and Maintenance: the EBV Paradigm	132
8.2.4.2	Vector Size Limitations	136
8.3	Minimalization Approaches	137
8.3.1	Oligomerizing S/MAR Modules: pMARS and Its Properties	139
8.3.2	Replicating Minicircles: a Solution with Great Promise	140
8.3.2.1	Establishment and Maintenance Parameters	141
8.3.2.2	Clonal Behavior	141
8.3.2.3	Bi-MC Systems	143
8.3.2.4	MC Size Reduction: "In Vivo Evolution"	144
8.3.2.5	Transcriptional Termination and Polyadenylation: an Intricate Interplay	146
8.3.2.6	Episomal Status: Proof and Persistence	147
8.3.3	Emerging Extensions and Refinements	149
8.3.3.1	Combination of Excision and RMCE Strategies	151
8.3.3.2	MC Withdrawal at Will	153
8.3.3.3	Pronuclear Injection and Somatic Cell Nuclear Transfer	155
8.3.3.4	From Cells to Organs	155

8.4	Summary and Outlook	156
	Acknowledgments	157
	References	158
<b>9</b>	<b>Magnetofection of Minicircle DNA Vectors</b>	<b>165</b>
	<i>Flavie Sicard, Cedric Sapet, Nicolas Laurent, Elodie Bertosio, Melanie Bertuzzi, and Olivier Zelphati</i>	
9.1	Introduction	165
9.2	Overview of Magnetofection Principles	167
9.3	Cellular Uptake	168
9.4	Diffusion through the Cytoplasm	169
9.5	Transgene Expression	169
9.6	Conclusions	172
	References	173
<b>10</b>	<b>Minicircle-Based Vectors for Nonviral Gene Therapy: <i>In Vitro</i> Characterization and <i>In Vivo</i> Application</b>	<b>177</b>
	<i>Dennis Kobelt, Jutta Aumann, Martin Schleeß, Marco Schmeer, Ulrike Stein, Peter M. Schlag, and Wolfgang Walther</i>	
10.1	Minicircle Technology for Nonviral Gene Therapy	177
10.2	Current Status of <i>In Vivo</i> Application of Minicircle Vectors	178
10.3	Jet Injection Technology for <i>In Vivo</i> Transfer of Naked DNA	180
10.4	Comparative Performance Analyses of Minicircle Vectors	183
10.5	<i>In Vivo</i> Application of Minicircle DNA by Jet Injection	185
	References	186
<b>11</b>	<b>Episomal Expression of Minicircles and Conventional Plasmids in Mammalian Embryos</b>	<b>189</b>
	<i>Wiebke Garrels, Khursheed Iqbal, and Wilfried A. Kues</i>	
11.1	Introduction	189
11.2	Fate of Plasmids and Minicircles After Injection into Mammalian Embryos	191
11.2.1	Minicircle- and Plasmid-Mediated Expression in Early Embryos and Fetuses	191
11.2.2	Expression of Functional Genes in Preimplantation Embryos	195
11.3	Discussion	198
	References	199
<b>12</b>	<b>Tissue-Targeted Gene Electrodélivery of Minicircle DNA</b>	<b>203</b>
	<i>Sophie Chabot, Muriel Golzio, and Justin Teissié</i>	
12.1	Introduction	203
12.2	Plasmid DNA Electrotransfer: From Principle to Technical Design	204
12.2.1	Mechanism of Gene Electrotransfer	204
12.2.2	Preclinical Applications	205
12.3	Implementation for Efficient Tissue-Targeted Gene Délivery	206

- 12.3.1 Design of DNA Vector 206
- 12.3.2 *In Vitro* Minicircle Electrotransfer 206
- 12.3.3 *In Vivo* MC Electrotransfer 207
  - 12.3.3.1 Muscle 207
  - 12.3.3.2 Tumor 208
  - 12.3.3.3 Skin 209
- 12.4 Conclusions 209
- Acknowledgments 209
- References 210

**13 Increased Efficiency of Minicircles Versus Plasmids Under Gene Electrotransfer Suboptimal Conditions: an Influence of the Extracellular Matrix 215**

*Vanessa Joubert, Franck M. André, Marco Schmeer, Martin Schleeß, and Luis M. Mir*

- 13.1 Introduction 215
- 13.2 Methods 215
  - 13.2.1 Cell Culture and Animals 215
  - 13.2.2 Minicircle and Plasmid 216
  - 13.2.3 Electrotransfer 216
  - 13.2.4 Determination of the Reporter Gene (Luciferase) Activity 216
  - 13.2.5 Data Analysis 217
- 13.3 Results 217
  - 13.3.1 *In Vitro* 217
  - 13.3.2 *In Vivo* 218
- 13.4 Discussion 220
- 13.5 Conclusions 223
- Acknowledgments 224
- References 224

**Index 227**